Loading clinical trials...

Exercise and Colon Cancer | Clinical Trials | Clareo Health

COMPLETEDNA

Exercise and Colon Cancer

The COURAGE Trial: Colon Recurrence and Aerobic Exercise: A Feasibility Study

NCT02250053•Abramson Cancer Center at Penn Medicine

Summary

Despite the success of surgery and chemotherapy among people with colon cancer, 30-50% of patients develop recurrent disease. Physical activity has emerged as a potential lifestyle intervention to reduce cancer recurrence and improve survival among people with colon cancer (CC). This pilot study aims to identify the dose-response effects of aerobic exercise on molecular and cellular pathways associated with physical activity and CC outcomes among patients with stage II and III CC.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. histologically confirmed TNM stage II-III CC;
•2. completed surgical resection and adjuvant chemotherapy (if applicable) within 1-24 months before entering the study;
•3. ≤120 min/wk of self-reported moderate or vigorous intensity physical activity using the Paffenbarger physical activity questionnaire;
•4. age ≥18 years;
•5. written physician approval;
•6. no additional surgery planned within the 6-month intervention (including colostomy reversal);
•7. ability to walk unaided for 6-minutes;
•8. no contraindications to exercise using the PA readiness questionnaire (PAR-Q), unless physician approves participation with specific knowledge of this contraindication.

Exclusion Criteria

•1. history of another primary invasive cancer (other than non-melanoma skin-cancer);
•2. evidence of metastatic CC (i.e., TNM M1);
•3. planning to receive any additional adjuvant chemotherapy;
•4. pregnant or breast feeding;
•5. unable to provide baseline blood sample;
•6. cardiac conditions, including the following:
•1. myocardial infarction or coronary revascularization procedure within prior 3 months;
•2. uncontrolled hypertension (systolic ≥180 mmHg or diastolic ≥100 mmHg);
•3. high-risk or uncontrolled arrhythmias;
•4. clinically significant valvular disease;
+3 more criteria

Locations (1)

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

December 1, 2015

Primary Completion Date

January 1, 2016

Completion Date

January 15, 2016

Last Updated

April 9, 2020

Enrollment

ACTUAL participants

Conditions

Stage II Colon CancerStage III Colon Cancer

Interventions

Exercise

OTHER

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

ACTIVE_NOT_RECRUITINGPHASE2

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

NCT03992456

Metastatic Colon AdenocarcinomaMetastatic Colorectal Carcinoma+28 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 9, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Exercise and Colon Cancer

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Adjuvant Chemotherapy in High Risk Stage II Colon Cancer